2-[4-(2-氰基苯基)哌嗪-1-基]-N-(3-甲基苯基)乙酰胺 | 630116-03-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 2-[4-(2-氰基苯基)哌嗪-1-基]-N-(3-甲基苯基)乙酰胺
• 英文名称: A 369508
• 英文别名: 2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl)acetamide；2-[4-(2-cyanophenyl)piperazin-1-yl]-N-(3-methylphenyl)acetamide
• CAS: 630116-03-9
• 化学式: C₂₀H₂₂N₄O
• 分子量: 334.421
• InChiKey: IPAGYDFLTXLPDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-(2-苯甲腈)哌嗪 以92%的产率得到2-[4-(2-氰基苯基)哌嗪-1-基]-N-(3-甲基苯基)乙酰胺
  参考文献：
  名称：

  Acetamides and benzamides that are useful in treating sexual dysfunction

  摘要：

  本发明涉及使用式(I)的化合物治疗性功能障碍，以及含有式(I)化合物的组合物用于治疗性功能障碍。

  公开号：

  US20040029887A1

文献信息

• Synthesis and functional activity of (2-aryl-1-piperazinyl)-N-(3-methylphenyl)acetamides: selective dopamine D4 receptor agonists
  作者：Mark A Matulenko、Ahmed A Hakeem、Teodozyi Kolasa、Masaki Nakane、Marc A Terranova、Marie E Uchic、Loan N Miller、Renjie Chang、Diana L Donnelly-Roberts、Marian T Namovic、Robert B Moreland、Jorge D Brioni、Andrew O Stewart

  DOI：10.1016/j.bmc.2004.04.035

  日期：2004.7

  Diaryl piperazine acetamides were identified as potent and selective dopamine D(4) receptor agonists. Our strategy is based on an amide bond reversal of an acid sensitive, dopamine D(4) receptor partial agonist, PD 168077. This reversal provided compounds with excellent potency and improved stability. Systematic evaluation of the substitution on the aryl piperazine portion revealed a significant effect

  二芳基哌嗪乙酰胺被确定为有效的和选择性的多巴胺D（4）受体激动剂。我们的策略基于对酸敏感的多巴胺D（4）受体部分激动剂PD 168077的酰胺键逆转。这种逆转为化合物提供了出色的效能和更高的稳定性。芳基哌嗪部分取代的系统评价显示对功能活性的显着影响。这些新的多巴胺D（4）激动剂的合成和生物学活性进行了讨论。
• Method of treatment for mental disorders
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US10098875B2

  公开（公告）日：2018-10-16

  The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D4 receptor agonist.

  本发明涉及一种治疗精神障碍的药物或方法，具体而言，包括鲁拉西酮或鲁拉西酮与D4受体激动剂的组合治疗多动症。
• Synthesis and activity of 2-[4-(4-[3H]-2-cyanophenyl)piperazinyl]-N-(2,4,6-[3H]3-3-methylphenyl)acetamide: a selective dopamine D4 receptor agonist and radioligand
  作者：Mark A. Matulenko、Bruce Surber、Leimin Fan、Teodozyi Kolasa、Masaki Nakane、Marc A. Terranova、Marie E. Uchic、Loan N. Miller、Renjie Chang、Diana L. Donnelly-Roberts、Marian T. Namovic、Robert B. Moreland、Jorge D. Brioni、Andrew O. Stewart

  DOI：10.1016/j.bmcl.2004.07.068

  日期：2004.10

  The first selective dopamine D-4 agonist radioligand is described. The synthesis of these piperazine radioligands relied on the transformation of brominated precursors 4a and 4b with tritium gas in the presence of a sensitive cyano functional group. The specific activity of these two radioligands was measured and [H-3]6b found to be suitable for use in D-4 saturation and competition binding studies. The synthesis, biological, and radioactivity of this new agonist radioligand as well as preliminary SAR will be discussed. (C) 2004 Elsevier Ltd. All rights reserved.
• ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION
  申请人：Abbott Laboratories

  公开号：EP1509213A2

  公开（公告）日：2005-03-02
• METHOD OF TREATMENT FOR MENTAL DISORDERS
  申请人：IKEDA Kazuhito

  公开号：US20120115879A1

  公开（公告）日：2012-05-10

  The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D 4 receptor agonist.